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Abstract
Background: Ectonucleotide pyrophosphatase/phosphodi-
esterase1 (ENPP1/PC-1) is a key modulator of the insulin sig-
naling pathway, and its common variant, K121Q, increases 
the susceptibility to diabetes and cardiovascular diseases. 
Objectives: The main objective of the present study was to 
investigate the association of ENPP1 K121Q polymorphism 
with the pathophysiology of metabolic syndrome (MetS) in 
a north Indian population. Methods: A total of 567 partici-
pants (303 MetS subjects and 264 healthy controls) were ex-
amined for ENPP1 genotypes and various clinical parame-
ters, including body mass index (BMI), waist circumference 
(WC), systolic and diastolic blood pressures (SBP/DBP), fast-
ing blood glucose (FBG), cholesterol, triglycerides (TG), high-
density lipoprotein, and insulin. Genotyping was performed 
using polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP). Statistical analysis of the data 
was done using SPSS. Results: Significant increases in BMI, 
WC, SBP, DBP, FBG, TG, low-density lipoprotein, insulin, and 
Homeostasis Model Assessment of insulin resistance (HOMA-
IR) and of beta-cell function (HOMA-BF) were observed in 
MetS patients compared to healthy controls. Logistic regres-
sion analysis of data demonstrated a nonsignificant associa-
tion of QQ and KQ+QQ genotypes with increased risk of 
MetS (OR [95% CI], 1.583 [0.455–5.507], p = 0.470 for QQ gen-
otypes and 1.097 [0.784–1.540], p = 0.587 for KQ+QQ geno-
types). Moreover, MetS subjects carrying Q alleles had sig-
nificantly higher levels of TG, insulin, body fat percentage, 
and insulin resistance as evident by higher values of HOMA-
IR. Conclusions: We conclude that ENPP1 K121Q functional 
variant enhances susceptibility to insulin resistance and dys-
lipidemia in MetS subjects of an Asian Indian population.
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Introduction
Metabolic syndrome (MetS) is a cluster of metabolic 
abnormalities comprised of abdominal obesity, hyperin-
sulinemia, hypertension, and dyslipidemia. India is wit-
nessing a depressing situation due to the escalating inci-
dence and prevalence of MetS in rural and urban popula-
tions [1–3]. Earlier data demonstrated that about one-third 
of the urban population in large cities in India had MetS 
[4]. The increase in the prevalence of MetS leads to in-
creased morbidity and mortality due to type 2 diabetes 
mellitus and cardiovascular disease in Asians [5–7]. It has 
been reported that the prevalence of MetS is 31.4% in an 
Indian population, and females (48.2%) are more affected 
than their male counterparts (16.3%) [3, 8]. The origins of 
MetS are complex and thought to involve metabolic, hor-
monal, genetic, and lifestyle interactions. Familial segre-
gation analysis, twin studies, and heredity studies clearly 
demonstrated the genetic basis of MetS [9]. Several candi-
date genes for defects in insulin signaling pathways have 
been suggested; however, only a few studies have reported 
positive associations between polymorphisms of genes in 
the insulin signaling pathway and insulin resistance [10]. 
Ectoenzyme nucleotide pyrophosphate phosphodi- 
esterase 1 (ENPP1), also known as plasma cell mem- 
brane glycoprotein 1 (PC-1), is a membrane glycoprotein 
that downregulates insulin signaling by interacting 
with the α-subunit of the insulin receptor [11]. A com-
mon missense single nucleotide polymorphism, K121Q 
(rs1044498) in exon 4 of the ENPP1 gene, has a glutamine 
substitution for lysine at codon 121 and was found to be 
associated with insulin resistance [12]. No study has been 
reported in north Indians, except our previous study [13], 
so we planned to investigate the possible association of 
the ENPP1 K121Q polymorphism with the risk of MetS 
in a north Indian population.
Material and Methods
Human Subjects
We included 567 participants (303 MetS subjects and 264 healthy 
controls) who were the participants of our ongoing study [14]. In 
brief, the North Indian Diabetes and Cardiovascular Disease Re-
search (NIDCVD) study was commenced in 2011 with the aim of 
investigating the interplay of genetic and environmental factors as-
sociated with diabetes and cardiovascular diseases in an Indian pop-
ulation. Informed written consent was obtained from all partici-
pants. All protocols were approved by the Institutional Ethics Com-
mittees of Postgraduate Institute of Medical Education and Research, 
Chandigarh, India. MetS was defined according to the NCEP-ATP 
III guidelines with an anthropometric modification of the waist cir-
cumference value that is specifically applicable to South Asians [15]. 
An individual was considered to have MetS when 3 or more of the 
following criteria were satisfied: (1) central obesity (waist circumfer-
ence ≥90 cm in men and ≥80 cm in women); (2) elevated blood 
pressure: systolic blood pressure ≥130 mm Hg, diastolic blood pres-
sure ≥85 mm Hg, or known treatment for hypertension; (3) elevat-
ed triglycerides (TG): fasting plasma TG ≥150 mg/dL (1.7 mmol/L) 
or drug treatment for elevated TG; (4) reduced high-density lipo-
protein cholesterol (HDL-C): fasting HDL-C < 40 mg/dL in men and 
< 50 mg/dL in women; and (5) hyperglycemia: elevated fasting glu-
cose > 110 mg/dL or previously diagnosed type 2 diabetes. All pa-
tients previously diagnosed with MetS and receiving medications 
for hypertension, diabetes, or dyslipidemia were included in the 
study and were evaluated for these risk factors. 
Anthropometric and Clinical Characteristics
All the anthropometric measurements were performed using 
standard procedures. Waist and hip circumference were measured 
with a nonstretchable metal tape. Height was measured with a stat-
ure meter and weight with a portable balance beam scale. Blood 
pressure was measured by an Omron blood pressure machine in 
sitting position from the left arm resting on the table, with legs un-
crossed and feet flat. The quantitative measurements, such as total 
lipid profile (total cholesterol [TC], TG, HDL, insulin, and creati-
nine), were recorded from the patients’ medical records if done 
within a maximum of 15 days before participation. Otherwise, 
these estimations were done in the lab using standard kits (Roche 
Diagnostics). Low-density lipoprotein cholesterol (LDL-C) level 
was calculated using the Friedewald formula, i.e., LDL-C = TC – 
[HDL-C – (TG in mg/dL/5)]. Fasting and random blood glucose 
levels were measured using a portable glucometer (Abbott Optium 
Xceed, USA). All quantitative estimations were done by following 
the manufacturer’s instructions using a biochemistry autoanalyzer. 
Derived Measures
Body mass index (BMI) was calculated using the Quetelet equa-
tion, i.e., BMI = weight in kilograms/height in meters squared. 
Waist to hip ratio (WHR) was calculated as the ratio of abdomen 
to hip circumferences. Anthropometric measurements used for 
the establishment of abdominal obesity were according to the cut-
off values for Asian Indians. Body fat percentage (BF%) was calcu-
lated according to the method of Lean et al. [16] using the follow-
ing formulae: BF% for men = [(0.567 × waist circumference in cm) 
+ (0.101 × age in years)] – 31.8; and BF% for women = [(0.438 × 
waist circumference in cm) + (0.221 × age in years)] – 9.4. Homeo-
stasis Model Assessment (HOMA) indices, such as insulin resis-
tance (HOMA-IR) and beta-cell function (HOMA-BF), were cal-
culated using the following formulae: HOMA-IR = [fasting insulin 
(µU/mL) × fasting blood glucose (mmol/L)]/22.5; and HOMA- 
BF = [20 × fasting insulin (µU/mL)]/fasting blood glucose 
(mmol/L) [17]. Abdominal obesity was defined according to the 
cutoffs proposed for South Asian Indians [18], i.e., WHR > 0.89 for 
men and WHR > 0.81 for women. BMI < 23 has been proposed as 
low risk, BMI 23–27.5 as increased risk, and BMI ≥27.5 as high risk 
for developing weight-related diseases in Asian populations. 
Amplification of ENPP1 K121Q Polymorphism 
Genomic DNA was extracted from the peripheral blood using 
the phenol/chloroform method. The K121Q polymorphism of 
ENPP1 polymorphism was detected by the polymerase chain reac-
tion-restriction fragment length polymorphism (PCR-RFLP) meth-
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od. The primer sequences were: F 5'GCA ATT CTG TGT TCA CTT 
TGG A3' and R 5'GAG CAC CTG ACC TTG ACA CA3'. The PCR 
was performed in a final volume of 25 µL, containing 20 ng of ge-
nomic DNA, 1.5 mmol/L MgCl2, 0.2 mmol/L of each deoxynucleo-
tide (Eppendorf, Germany), 0.5 pmol of each primer, and 1 unit of 
Taq DNA polymerase (New England Biolabs, USA). The initial de-
naturing was set up at 94  ° C for 5 min followed by 30 cycles of de-
naturation at 94  ° C for 50 s, annealing at 55  ° C for 40 s, and extension 
at 72  ° C for 40 s, and the final extension was at 72  ° C for 5 min. The 
amplified PCR product (208 bp) was digested with Ava II (New Eng-
land Biolabs) at 37  ° C for 15 h with 1× NEB buffer 4 in a final volume 
of 15 µL; the reaction was stopped by heat inactivation for 20 min at 
65  ° C. Results were then analyzed on 2% agarose gel. 
Statistical Analysis
Results were expressed as means ± standard deviations. χ2 anal-
ysis was used to test the significance of differences in frequencies. 
Group comparisons were done using unpaired t tests. All p values 
< 0.05 (two-tailed) were considered as significant. Logistic regres-
sion analyses were performed to correlate various clinical param-
eters with disease and to calculate odds ratios (ORs) and 95% con-
fidence intervals (CIs) for each risk factor. Statistical analysis was 
performed using SPSS for Windows, version 20.
Results
Baseline Characteristics of the Study Subjects
In the present study, we assessed the interplay of 
K121Q polymorphism in the ENPP1 gene and risk of 
MetS in 567 participants (303 MetS subjects and 264 
healthy controls). The baseline characteristics of the study 
participants are summarized in Table 1. MetS patients 
demonstrated a significantly higher mean age than the 
control subjects (59.0 vs. 54.7 years, p = < 0.001). MetS 
patients had a pronounced abdominal adiposity reflected 
by their significantly higher waist circumference (38.2 ± 
43.9 inches in patients vs. 34.7 ± 4.3 inches in controls, 
p = < 0.001) and WHR (1.0 ± 0.1 in patients vs. 0.93 ± 0.06 
in controls, p = 0.000). Also, significantly higher values of 
BMI and elevated blood pressure were observed in MetS 
patients compared to control subjects (p < 0.001). Follow-
ing stratification of the data based on the new BMI cutoffs 
by the WHO Expert Consultation (2004), we observed 
Table 1. Anthropometric and clinical measurements in the MetS and control subjects stratified by sex and disease status
Characteristics Male subjects Female subjects Total subjects
n mean SD p value n mean SD p value n mean SD p value
Age, years
Control 113 57.8 14.7 0.204 151 52.4 13.6 0.000 264 54.7 14.3 0.000
MetS 156 59.7 10.2 147 58.3 10.6 303 59.0 10.4
BMI
Control 113 26.1 4.3 0.015 151 26.9 5.1 0.000 264 26.6 4.8 0.000
MetS 156 27.4 3.8 147 29.8 4.9 303 28.6 4.5
WC, inch
Control 113 36.1 4.4 0.000 151 33.7 4.1 0.000 264 34.7 4.3 0.000
MetS 156 38.6 3.5 147 37.9 4.3 303 38.2 3.9
HC, inch
Control 113 37.1 3.2 0.000 151 37.6 3.9 0.000 264 37.4 3.6 0.000
MetS 156 38.6 3.0 147 40.1 4.0 303 39.3 3.6
WHR
Control 113 0.97 0.07 0.000 151 0.9 0.1 0.000 264 0.9 0.1 0.000
MetS 156 1.00 0.06 147 0.9 0.1 303 1.0 0.1
Systolic BP, mm Hg
Control 113 141 25 0.003 151 134 26 0.000 264 137 26 0.000
MetS 156 149 21 147 151 24 303 150 23
Diastolic BP, mm Hg
Control 113 83 13 0.030 151 81 13 0.000 264 82 13 0.000
MetS 156 86 12 147 87 13 303 87 12
All p values <0.05 (two-tailed) were considered significantly different. MetS, metabolic syndrome; SD, standard deviation; BMI, body 
mass index; WC, waist circumference; HC, hip circumference; WHR, waist to hip ratio; BP, blood pressure. 
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pronounced central obesity in both patients and controls, 
even at the lowest BMI values (< 23). 
Table 2 shows the clinical characteristics of MetS pa-
tients and healthy subjects stratified by sex and disease 
status. MetS subjects exhibited significantly higher values 
of fasting glucose (164.8 ± 66.5 vs. 96 ± 7.5 mg/dL, p < 
0.001); TG (184 ± 90.1 vs. 157.7 ± 82.0 mg/dL, p < 0.001); 
glycosylated hemoglobin (8.2 ± 2.4 vs. 6.8 ± 2.0%, p < 
0.001); and insulin (10.8 ± 6.4 vs. 8.3 ± 4.5 IU/mL, p < 
0.001) as well as reduced HDL-C (38.5 ± 11.7 vs. 44.6 ± 
10.9 mg/dL, p < 0.001) compared to control subjects. 
MetS patients demonstrated insulin resistance and beta-
Table 2. Biochemical parameters in the MetS and control subjects stratified by sex and disease status
Clinical parameters Male Female Total subjects
mean SD p value mean SD p value mean SD p value
Glucose, mg/dL
Control 96.4 7.2 0.000 96.6 8.6 0.000 96.0 7.5 0.000
MetS 164.3 66.5 165.4 66.7 164.8 66.5
TC, mg/dL
Control 150.4 31.1 0.967 158.8 29.7 0.023 154.5 30.4 0.135
MetS 183.7 50.7 192.9 47.5 188.0 49.3
TG, mg/dL
Control 174.2 81.3 0.415 145.5 80.8 0.002 157.7 82.0 0.003
MetS 184.6 87.8 183.4 92.9 184.0 90.1
HDL-C, mg/dL
Control 42.5 9.9 0.001 46.2 11.4 0.000 44.6 10.9 0.000
MetS 36.9 11.6 40.3 11.6 38.5 11.7
LDL-C, mg/dL
Control 106.1 53.7 0.613 103.5 34.6 0.024 104.6 43.6 0.074
MetS 109.8 48.0 115.9 42.5 112.7 45.5
VLDL-C, mg/dL
Control 34.8 16.3 0.415 29.1 16.2 0.002 31.5 16.4 0.003
MetS 36.9 17.6 36.7 18.6 36.8 18.0
Creatinine, mg/dL
Control 0.95 0.43 0.789 0.78 0.22 0.953 0.85 0.33 0.700
MetS 0.94 0.27 0.79 0.32 0.87 0.30
Insulin, IU/mL
Control 8.3 4.3 0.001 8.4 4.6 0.012 8.3 4.5 0.000
MetS 11.1 6.1 10.5 6.7 10.8 6.4
Body fat, %
Control 25.6 6.3 0.000 39.2 5.8 0.000 33.4 9.1 0.000
MetS 29.3 4.9 45.3 5.1 37.1 9.4
HOMA-IR
Control 2.15 1.16 0.000 2.01 1.11 0.000 2.07 1.13 0.000
MetS 4.27 2.84 4.09 2.83 4.19 2.83
HOMA-BF
Control 95.6 54.9 0.000 92.1 50.3 0.000 93.5 52.0 0.000
MetS 61.3 56.0 56.4 50.0 59.0 53.3
p values <0.05 (two-tailed) were considered significantly different between MetS and controls. MetS, metabolic syndrome; SD, 
standard deviation; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; HOMA-IR, Homeostasis Model Assessment of insulin resistance; 
HOMA-BF, Homeostasis Model Assessment of beta-cell function. 
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cell dysfunction evidenced by increased values of HOMA-
IR and decreased values of HOMA-BF, respectively, in 
both sexes compared to control subjects. Also, signifi-
cantly high BF% was observed in MetS patients compared 
to healthy control subjects (p < 0.001). Nevertheless, no 
significant differences were observed in TC, LDL-C, and 
creatinine levels of MetS patients compared to control 
subjects (Table 2). 
K121Q Polymorphism in ENPP1 Gene and Risk of 
MetS
The distribution of genotypes and allele frequencies 
of the K121Q polymorphism of the ENPP1 gene are giv-
en in Table 3. The distribution of KK genotype was 
slightly higher in control subjects than in MetS patients 
(61 vs. 58.7%). Subjects with MetS were found to have a 
slightly higher frequency of KQ and QQ genotypes than 
control subjects. Very few subjects with QQ genotypes 
were observed, so we also merged KQ and QQ genotypes 
to test for an association of the K121Q polymorphism in 
ENPP1 gene with the risk of MetS. The frequency of the 
K allele was similar in MetS cases and control subjects 
(p = 0.639). 
Logistic regression analysis of data demonstrated a 
nonsignificant association of QQ and KQ+QQ genotypes 
with increased risk of MetS (OR [95% CI], 1.583 [0.455–
5.507], p = 0.470 for QQ genotypes and 1.097 [0.784–
1.540], p = 0.587 for KQ+QQ genotypes, respectively). In 
order to evaluate the correlation of the K121Q polymor-
phism of the ENPP1 gene with metabolic traits, various 
clinical parameters were analyzed in all participants with 
KK and KQ/QQ genotypes (Table 4). The results showed 
that MetS subjects carrying KQ+QQ genotypes had sig-
nificantly higher levels of TG (174 vs. 199 mg/dL, p = 
0.032) and VLDL-C (34.9 vs. 39.8 mg/dL, p = 0.032) than 
those carrying KK genotypes. We further evaluated the 
distribution of the K121Q polymorphism in MetS patients 
and healthy controls. MetS subjects carrying QQ geno-
types showed significantly higher values of HOMA-IR 
(13.5 ± 1.75) compared to those carrying KK (4.0 ± 2.23) 
and KQ genotypes (3.7 ± 2.4). Moreover, MetS subjects 
carrying Q alleles had significantly higher levels of TG, 
insulin, and BF% than healthy controls. Nevertheless, no 
significant correlations were observed between the geno-
types of the ENPP1 K121Q variant and other metabolic 
traits in MetS patients or control subjects (Table 4).
Discussion
The incidence and prevalence of MetS is rising globally. 
The situation of MetS in India has reached an epidemic 
scale. The findings of previous studies provide evidence for 
the escalation of MetS and its determinants [5, 19–21]. It 
has been reported that ENPP1 gene modulates insulin sig-
naling by inhibiting the insulin receptor’s tyrosine kinase 
activity and confers insulin resistance [22]. Further, this 
effect is modified by the K121Q polymorphism of ENPP1 
gene [12]. The consistency of the prediction of the effect of 
the ENPP1 K121Q allele on type 2 diabetes supports the 
view that the ENPP1 K121Q allele is the functional variant 
that affects the phenotype per se [11, 23]. During the last 
Table 3. Distribution of genotypes and allelic frequencies of ENPP1 K121Q variant in MetS and control subjects
Controls, 
n (%)
MetS subjects, 
n (%) 
Test of association
OR (95% CI) p value
Genotypes
KK 161 (61.0) 178 (58.7) reference
KQ 99 (37.5) 118 (38.9) 1.078 (0.766–1.517) 0.666
QQ 4 (1.5) 7 (2.3) 1.583 (0.455–5.507) 0.470
KQ+QQ 103 (39.0) 125 (41.3) 1.097 (0.784–1.540) 0.587
Total genotypes 264 303
Allele frequencies
K 421 (0.80) 474 (0.78) reference
Q 107 (0.20) 132 (0.22) 1.072 (0.801–1.435) 0.639
Total alleles 528 606
MetS, metabolic syndrome; OR, odds ratio; CI, confidence interval.
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decade, genetic association studies have established a pos-
itive association between ENPP1 K121Q polymorphism 
and the pathophysiology of insulin resistance or type 2 di-
abetes [24–30], obesity [31, 32], and other MetS [30, 33–
36]. However, studies of the clinical impact of the K121Q 
polymorphism have generated conflicting results. 
The present study did not predict the association of the 
ENPP1 K121Q polymorphism with MetS and related 
quantitative metabolic traits in this population; however, 
the sample had sufficient power for detecting the associa-
tion at a moderate level. Among MetS individuals carrying 
the KQ/QQ genotype, higher values of TG and insulin re-
sistance reflected by HOMA-IR indicated insulin resis-
tance in MetS patients. Recently, a study has demonstrat-
ed that the ENPP1 gene polymorphism is associated with 
hypertriglyceridemia and may contribute to insulin resis-
tance or MetS [37]. Our results are similar to those of a 
vast majority of studies carried out in different popula-
tions. No evidence for an association of the ENPP1 K121Q 
variant with insulin resistance or type 2 diabetes was re-
ported in Japanese [38], Spanish [39], Danish Caucasian 
[40], North Indian [13], UK Caucasian [41], and Chinese 
[42] populations. Besides, a great difference in allele fre-
quencies was observed between the different populations 
[26, 36, 43]. It is possible that the susceptibility induced by 
the ENPP1 K121Q gene polymorphism is modulated by 
Table 4. Correlation of ENPP1 K121Q genotypes with measures of quantitative traits in MetS and control subjects
Characteristics/
genotypes
Control subjects MetS subjects Characteristics/
genotypes
Control subjects MetS subjects
mean SD p 
value
mean SD p 
value
mean SD p 
value
mean SD p 
value
Age, years TG, mg/dL
KK 55.3 14.1 0.405 58.5 10.1 0.314 KK 153.1 82.5 0.424 174.3 83.4 0.032
KQ+QQ 53.8 14.6 59.7 10.8 KQ+QQ 163.6 81.7 199.0 97.9
BMI HDL-C, mg/dL
KK 26.6 5.2 0.924 28.8 4.7 0.239 KK 46.9 10.9 0.003 38.0 11.8 0.413
KQ+QQ 26.6 4.1 28.2 4.3 KQ+QQ 41.7 10.2 39.2 11.6
WC, inch LDL-C, mg/dL
KK 34.6 4.4 0.569 38.4 3.8 0.300 KK 105.3 48.0 0.807 112.4 46.6 0.900
KQ+QQ 34.9 4.3 38.0 4.1 KQ+QQ 103.6 37.4 113.1 44.1
HC, inch VLDL-C, mg/dL
KK 37.47 3.67 0.753 39.53 3.59 0.255 KK 30.6 16.5 0.424 34.9 16.7 0.032
KQ+QQ 37.33 3.51 39.04 3.70 KQ+QQ 32.7 16.3 39.8 19.6
WHR Creatinine, mg/dL
KK 0.92 0.08 0.218 0.97 0.07 0.937 KK 0.87 0.39 0.580 0.88 0.29 0.478
KQ+QQ 0.94 0.08 0.97 0.06 KQ+QQ 0.84 0.25 0.85 0.32
Systolic BP, mm Hg Insulin, IU/mL
KK 139.51 26.29 0.052 149.15 21.65 0.432 KK 8.5 4.7 0.680 9.50 6.5 0.008
KQ+QQ 133.20 24.50 151.22 23.98 KQ+QQ 8.2 4.2 11.6 6.0
Diastolic BP, mm Hg Body fat, %
KK 83.17 13.49 0.021 86.96 12.28 0.576 KK 33.8 8.9 0.425 36.2 8.9 0.042
KQ+QQ 79.44 11.39 86.15 12.27 KQ+QQ 32.8 9.4 39.3 10.0
Glucose, mg/dL HOMA-IR
KK 96.1 7.8 0.699 166.1 67.6 0.682 KK 2.10 1.19 0.746 2.93 2.98 0.020
KQ+QQ 95.7 7.0 163.0 65.0 KQ+QQ 2.03 1.04 3.65 2.50
TC, mg/dL HOMA-BF
KK 182.8 49.7 0.504 185.2 51.0 0.275 KK 93.6 51.4 0.994 64.0 57.5 0.075
KQ+QQ 178.0 37.6 192.1 46.5 KQ+QQ 93.5 53.4 51.3 45.1
p values <0.05 (two-tailed) were considered significantly different between genotypes. MetS, metabolic syndrome; SD, standard de-
viation; BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist to hip ratio; BP, blood pressure; TC, to-
tal cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, 
very-low-density lipoprotein cholesterol; HOMA-IR, Homeostasis Model Assessment of insulin resistance; HOMA-BF, Homeostasis 
Model Assessment of beta-cell function. 
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interactions with other ethnicity-specific genetic or envi-
ronmental factors. Previous studies in Indians and other 
ethnic groups demonstrated that those carrying the 
ENPP1 K121Q variant have an increased risk of develop-
ing type 2 diabetes and cardiovascular diseases [25, 28, 44, 
45]. The same genetic determinants might have a different 
contribution to the etiology of a complex disease when 
interacting with different environmental factors. ENPP1 
K121Q may contribute to the determination of an ethnic 
susceptibility to insulin resistance and type 2 diabetes. 
However, the present data demonstrated the association 
of the ENPP1 K121Q polymorphism with insulin resis-
tance measured by HOMA-IR, and our results are in line 
with various studies carried out in other parts of the world 
[12, 22, 24, 31]. We did not find any association with oth-
er metabolic quantitative traits, such as BMI, WHR and 
TC, LDL-C, and insulin levels. However, the K121Q poly-
morphism may be associated with insulin resistance and 
dyslipidemia reflected by low HDL and hypertriglyceride-
mia in MetS subjects. The reason for the apparent discrep-
ancies between studies, including ours, which have evalu-
ated the pathogenic impact of the K121Q variant, is far 
from obvious. It is possible that the susceptibility induced 
by the polymorphism is modulated by interactions with 
other ethnicity-specific genetic or environmental factors 
and that the phenotypic expression of the variant will, 
therefore, be different in various ethnic populations. In 
this regard, it is emphasized that the frequency of the 
K121Q polymorphism varies considerably between dif-
ferent ethnic groups. Further, large studies are necessary 
to ascertain the validity of the described genotype-pheno-
type relationship in an Asian Indian population. In con-
clusion, our data suggest that the ENPP1 K121Q polymor-
phism may be associated with insulin resistance and dys-
lipidemia in MetS subjects of a north Indian population. 
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